- Home
- RMMZ vs JNJ Comparison
RMMZ vs JNJ Comparison
Compare RMMZ & JNJ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMMZ | JNJ |
|---|---|---|
| Founded | 2022 | 1886 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 589.2B |
| IPO Year | N/A | 1944 |
Fundamental Metrics
Financial Performance| Metric | RMMZ | JNJ |
|---|---|---|
| Price | $15.12 | $243.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $227.29 |
| AVG Volume (30 Days) | 25.6K | ★ 9.2M |
| Earning Date | 01-01-0001 | 01-21-2026 |
| Dividend Yield | ★ 7.33% | 2.13% |
| EPS Growth | N/A | ★ 71.26 |
| EPS | 0.82 | ★ 11.03 |
| Revenue | N/A | ★ $94,193,000,000.00 |
| Revenue This Year | N/A | $6.63 |
| Revenue Next Year | N/A | $7.21 |
| P/E Ratio | ★ $19.41 | $22.17 |
| Revenue Growth | N/A | ★ 5.08 |
| 52 Week Low | $12.92 | $141.50 |
| 52 Week High | $16.99 | $246.35 |
Technical Indicators
Market Signals| Indicator | RMMZ | JNJ |
|---|---|---|
| Relative Strength Index (RSI) | 63.48 | 83.07 |
| Support Level | $15.00 | $237.40 |
| Resistance Level | $15.15 | $246.35 |
| Average True Range (ATR) | 0.14 | 3.66 |
| MACD | 0.04 | 0.87 |
| Stochastic Oscillator | 71.26 | 90.12 |
Price Performance
Historical ComparisonAbout RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About JNJ Johnson & Johnson
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.